← Leaderboards
Iraklis Ilias Pipinos
University Of Nebraska Medical Center
$11,841,015
Attributed
$16,041,208
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,041,208 · 5
VA$0 · 2
By mechanism
R01$15,387,808 · 4
K08$653,400 · 1
I01$0 · 1
I21$0 · 1
Top collaborators
- George Pasco Casale6 shared
- Mark A Carlson5 shared
- Sara A Myers5 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Jason Mactaggart$3,355,844
- George Pasco Casale$2,836,836
- Mark A Carlson$3,817,031
Others in their field
Top investigators on “Walking”
- Marco Pahor · Wake Forest University Health Sciences$86,361,568
- Richard Leonard · Battelle Memorial Institute$83,835,536
- Mary McGrae McDermott · Northwestern University$61,875,986
- Kathryn H Kirby · Battelle Memorial Institute$61,324,448
- Julianne L Imperato-McGinley · Weill Medical College Of Cornell Univ$37,304,492
- Dalane W Kitzman · Wake Forest University$33,463,174
Research focus
WalkingArteriesMuscleIschemiaPeripheral Arterial DiseaseClaudicationMyopathyAtherosclerosisPainAffectProtocols DocumentationLower ExtremityMitochondriaFunctional DisorderProceduresQuality Of LifePerformanceBaseMeasurementRestGaitLaboratoriesLimb StructureGangrene
Grant awards (31)
MitoQ treatment of claudication: myofiber and micro-vessel pathology$566,185
R01 · FY2025 · AG · contact PI
Oxygen-guided supervised exercise therapy in peripheral artery disease.$0
I21 · FY2025 · VA · contact PI
MitoQ treatment of claudication: myofiber and micro-vessel pathology$595,289
R01 · FY2024 · AG · contact PI
Exoskeleton footwear to improve walking performance and subject-reported preference.$0
I01 · FY2024 · VA
Oxygen-guided supervised exercise therapy in peripheral artery disease.$0
I21 · FY2024 · VA · contact PI
MitoQ treatment of claudication: myofiber and micro-vessel pathology$597,183
R01 · FY2023 · AG · contact PI
Effect of cell-based therapies on functional, hemodynamic, and histologic outcomes in a porcine model of peripheral arterial disease$582,670
R01 · FY2023 · AG · contact PI
Exoskeleton footwear to improve walking performance and subject-reported preference.$0
I01 · FY2023 · VA
MitoQ treatment of claudication: myofiber and micro-vessel pathology$631,128
R01 · FY2022 · AG · contact PI
Effect of cell-based therapies on functional, hemodynamic, and histologic outcomes in a porcine model of peripheral arterial disease$592,674
R01 · FY2022 · AG · contact PI
Exoskeleton footwear to improve walking performance and subject-reported preference.$0
I01 · FY2022 · VA
Effect of cell-based therapies on functional, hemodynamic, and histologic outcomes in a porcine model of peripheral arterial disease$603,929
R01 · FY2021 · AG · contact PI
Exoskeleton footwear to improve walking performance and subject-reported preference.$0
I01 · FY2021 · VA
Effect of cell-based therapies on functional, hemodynamic, and histologic outcomes in a porcine model of peripheral arterial disease$614,558
R01 · FY2020 · AG · contact PI
Exoskeleton footwear to improve walking performance and subject-reported preference.$0
I01 · FY2020 · VA
Ramipril treatment of claudication: oxidative damage and muscle fibrosis$935,739
R01 · FY2019 · AG · contact PI
Effect of cell-based therapies on functional, hemodynamic, and histologic outcomes in a porcine model of peripheral arterial disease$670,262
R01 · FY2019 · AG · contact PI
Ramipril treatment of claudication: oxidative damage and muscle fibrosis$942,286
R01 · FY2018 · AG · contact PI
Ramipril treatment of claudication: oxidative damage and muscle fibrosis$942,286
R01 · FY2017 · AG · contact PI
Ramipril treatment of claudication: oxidative damage and muscle fibrosis$936,115
R01 · FY2016 · AG · contact PI
Ramipril treatment of claudication: oxidative damage and muscle fibrosis$948,740
R01 · FY2015 · AG · contact PI
Mitochondrial dysfunction, oxidative damage and inflammation in claudication$1,050,368
R01 · FY2014 · AG · contact PI
Mitochondrial dysfunction, oxidative damage and inflammation in claudication$992,598
R01 · FY2013 · AG · contact PI
Mitochondrial dysfunction, oxidative damage and inflammation in claudication$1,050,368
R01 · FY2012 · AG · contact PI
Mitochondrial dysfunction, oxidative damage and inflammation in claudication$1,050,695
R01 · FY2011 · AG · contact PI
Mitochondrial dysfunction, oxidative damage and inflammation in claudication$1,084,735
R01 · FY2010 · AG · contact PI
Mitochondriopathy of Chronically Ischemic Muscle$130,680
K08 · FY2009 · HL · contact PI
Mitochondriopathy of Chronically Ischemic Muscle$130,680
K08 · FY2008 · HL · contact PI
Mitochondriopathy of Chronically Ischemic Muscle$130,680
K08 · FY2007 · HL · contact PI
Mitochondriopathy of Chronically Ischemic Muscle$130,680
K08 · FY2006 · HL · contact PI
Mitochondriopathy of Chronically Ischemic Muscle$130,680
K08 · FY2005 · HL